Novel use of Kaplan-Meier methods to explain age and gender differences in hypertension control rates

被引:24
作者
Bailey, Kent R. [1 ]
Grossardt, Brandon R. [1 ]
Graves, John W. [2 ]
机构
[1] Mayo Clin, Coll Med, Div Biostat, Dept Hlth Sci Res, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Div Nephrol & Hypertens, Rochester, MN 55905 USA
关键词
hypertension; survival analysis; antihypertensive medication; aging; gender;
D O I
10.1161/HYPERTENSIONAHA.107.101659
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Despite 40 years of research demonstrating the efficacy of antihypertensive medications for lowering blood pressure and decreasing cardiovascular disease, hypertension control rates worldwide remain low. We explored here how both medication efficacy rates and patient/physician decision-making (discontinuation rates) affect overall hypertension control rates. To do this we introduced the use of Kaplan-Meier methodology to predict hypertension control rates separately within age strata. An important aspect of our analysis is the use of a "treatment intensity score," including both the number of agent(s) and the percentage of maximal dose of agent( s). We investigated how blood pressure control rates vary with age, gender, and treatment intensity. Our analysis found that both efficacy and discontinuation rates at different treatment intensities vary with age and gender, so that for each increase in age by 1 decade, the log hazard of achieving controlled blood pressure at any given intensity decreases by 0.10 in men and 0.20 in women. Overall hypertension control rates ranged from 80.8% for persons age 15 to 39 years to only 42.1% for persons age >= 80 years. Our analysis more accurately represents achievable hypertension control rates, with differences by gender, than previous work, because we investigated the contributions of efficacy and treatment aggressiveness in the control of hypertension.
引用
收藏
页码:841 / 847
页数:7
相关论文
共 26 条
  • [21] PRIMATESTA P, 2006, J HYPERTENS, V24, P1193
  • [22] Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
    Staessen, JA
    Fagard, R
    Thijs, L
    Celis, H
    Arabidze, GG
    Birkenhager, WH
    Bulpitt, CJ
    deLeeuw, PW
    Dollery, CT
    Fletcher, AE
    Forette, F
    Leonetti, G
    Nachev, C
    OBrien, ET
    Rosenfeld, J
    Rodicio, JL
    Tuomilehto, J
    Zanchetti, A
    [J]. LANCET, 1997, 350 (9080) : 757 - 764
  • [23] Rate and determinants of 10-year persistence with antihypertensive drugs
    Van Wijk, Boris L. G.
    Klungel, Olaf H.
    Heerdink, Eibert R.
    de Boer, Anthonius
    [J]. JOURNAL OF HYPERTENSION, 2005, 23 (11) : 2101 - 2107
  • [24] Outpatient hypertension treatment, treatment intensification, and control in western Europe and the United States
    Wang, Y. Richard
    Alexander, G. Caleb
    Stafford, Randall S.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (02) : 141 - 147
  • [25] Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review
    Wetzels, GEC
    Nelemans, P
    Schouten, JS
    Prins, MH
    [J]. JOURNAL OF HYPERTENSION, 2004, 22 (10) : 1849 - 1855
  • [26] THE PERSISTENT PROBLEM OF POOR BLOOD-PRESSURE CONTROL
    WINICKOFF, RN
    MURPHY, PK
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (08) : 1393 - 1396